Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline

https://ift.tt/Kl9DIjw

 

from Sanofi - Aventis Groupe https://ift.tt/ZbBke74
via IFTTT